For people with HIV taking tesamorelin, losing belly fat was linked to thicker, denser muscles in the abdominal and rectus areas.

For HIV patients with belly fat on tesamorelin, losing belly fat was linked to better muscle density in their abdominal and rectus muscles.

For HIV patients with belly fat who responded to this drug, taking tesamorelin for 6 months made their trunk muscles less fatty and more dense, like turning soft muscle into firmer muscle.

HIV patients with belly fat who responded to tesamorelin saw better lean muscle quality in their abdominal and rectus muscles, with improvements of 1.39 and 1.78 units respectively compared to placebo after 26 weeks.

HIV patients with belly fat who responded to tesamorelin had bigger rectus and psoas muscles (0.44 and 0.46 cm² larger) compared to placebo after 26 weeks.

HIV patients with belly fat who responded to tesamorelin had more lean muscle mass in all four trunk muscles, with increases between 0.64 and 1.08 cm² compared to placebo after 26 weeks.